There are currently 12 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are .
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criter... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/21/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Homewood, Alabama +320 locations
Conditions: Multiple Sclerosis
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: University of Alabama at Birmingham- Site Number : 8401135, Birmingham, Alabama +357 locations
Conditions: Multiple Sclerosis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
NCT05704361
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Stanford University Medical Center, Stanford, California +31 locations
Conditions: Multiple Sclerosis
Register for Updates
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition
NCT05781113
Recruiting
To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS display clinically significant gait impairments. Initial gait lab "gold standard" data indicate that the Artificial Intelligence (AI)-based digital biomarker will prove to be highly effective at dete... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Sclerosis
Register for Updates
My MS and My Menstrual Cycle
NCT06832293
Recruiting
The goal of this observational study is to understand how MS symptoms change during different phases of the menstrual cycle in individuals who menstruate living with MS (Multiple Sclerosis). The main questions it aims to answer are: 1. Does fatigue get worse during certain phases of the menstrual cycle? 2. How do symptoms like thinking skills, pain, and mobility change throughout the cycle? Participants will: * Use the My Normative app to track their menstrual cycle and MS symptoms. * Comple... Read More
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
03/21/2025
Locations: University of Calgary, Calgary, Alberta +1 locations
Conditions: Multiple Sclerosis, Menstrual Cycle
Register for Updates
Cannabis as a Complementary Treatment in Multiple Sclerosis
NCT05092191
Recruiting
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) afflicting over 77,000 Canadians. Unfortunately, the therapeutic arsenal to relieve MS symptoms is limited. It is therefore essential to develop better approaches to treat the symptoms of MS. The use of cannabis for recreational purposes is now legal in Canada. However, for many years, people with Multiple Sclerosis (PwMS) have used cannabis either to relax, to reduce pain and spasticity, or to improve sleep a... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/10/2024
Locations: CRCHUM, Montreal, Quebec
Conditions: Multiple Sclerosis
Register for Updates
EMG Biofeedback Training to Improve Balance in Individuals with Multiple Sclerosis
NCT06461741
Recruiting
The goal of this clinical trial is to test the impact of a novel dual-task EMG Biofeedback training method for improving balance in individuals living with multiple sclerosis. The main question\[s\] it aims to answer are: * Does dual-task EMG biofeedback training deliver lasting balance benefits up to 3 months following the intervention? * Are the benefits greater than those for participation in traditional balance training exercises? * Do the benefits vary with the severity of disability? Par... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/29/2024
Locations: McMaster University, Hamilton, Ontario
Conditions: Multiple Sclerosis
Register for Updates
Pharmacogenomics of Drug Safety in Multiple Sclerosis
NCT01118130
Recruiting
To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after exposure to beta-interferon for MS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: MS Clinic UBC Hospital, Vancouver, British Columbia +4 locations
Conditions: Multiple Sclerosis
Register for Updates
Exercise Effects in Multiple Sclerosis
NCT05496881
Recruiting
A growing body of work suggests that regular exercise can support symptom management and improve physical function for people living with multiple sclerosis (MS). Although exercise is known to be beneficial for managing many symptoms related to MS, its effects on the central nervous system, and whether these effects change with different types of exercise, are not well understood. Here, the investigators have designed a clinical trial that compares the effects of distinct exercise protocols on a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: University of Regina, Regina, Saskatchewan
Conditions: Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis
Register for Updates
Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis
NCT05661266
Recruiting
The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in multiple sclerosis (MS) patients to further build up a database of MS patients and train a machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Genge Partners, Inc., Montreal, Quebec
Conditions: Multiple Sclerosis
Register for Updates
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
NCT05061953
Recruiting
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by MS and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2023
Locations: The Neuro, Montreal, Quebec +1 locations
Conditions: Multiple Sclerosis
Register for Updates